Evidence map›Paper›PMID 30660650›Full record

ArticleCancer letters2019

Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.

Yanhua Chen, Lajos Gera, Shumin Zhang, Xin Li, Yang Yang, Kenza Mamouni, Alyssa Y Wu, HongYan Liu, Omer Kucuk, Daqing Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. A Preliminary Evaluation ofPharmaceutics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Yanhua ChenDepartment of Hand Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Molecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Lajos GeraDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, School of Medicine, Aurora, CO, USA.
Shumin ZhangDepartment of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Xin LiMolecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Yang YangMolecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kenza MamouniMolecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Alyssa Y WuChamblee Charter High School, Atlanta, GA, USA.
HongYan LiuMolecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Omer KucukDepartment of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Daqing WuMolecular Oncology and Biomarkers Program, Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA; Department of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; MetCure Therapeutics LLC, Atlanta, GA, USA. Electronic address: dwu@augusta.edu.
Augusta University · USEmory University · USUnion Hospital · CNInternational Charter School · USUniversity of Colorado Anschutz Medical Campus · US

Funding

EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer MetastasisR21CA164612 · NCI · EMORY UNIVERSITY · PI WU, DAQING · 2012 to 2013
$363k
Novel small-molecule targeted therapy for prostate cancerR41CA206725 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2016 to 2016
$225k
Small-molecule therapy for metastatic prostate cancerR41CA217491 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2017 to 2017
$225k
A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate CancerR41CA186498 · NCI · METCURE THERAPEUTICS, LLC · PI WU, DAQING · 2015 to 2015
$161k
NCI NIH HHS R21 CA164612NCI NIH HHS R41 CA186498NCI NIH HHS R41 CA206725NCI NIH HHS R41 CA217491
6 · The paper itself

Abstract

Bone metastasis is a major cause of prostate cancer (PCa) mortality. Although docetaxel chemotherapy initially extends patients' survival, in most cases PCa becomes chemoresistant and eventually progresses without a cure. In this study, we developed a novel small-molecule compound BKM1972, which exhibited potent in vitro cytotoxicity in PCa and other cancer cells regardless of their differences in chemo-responsiveness. Mechanistic studies demonstrated that BKM1972 effectively inhibited the expression of anti-apoptotic protein survivin and membrane-bound efflux pump ATP binding cassette B 1 (ABCB1, p-glycoprotein), presumably via signal transducer and activator of transcription 3 (Stat3). BKM1972 was well tolerated in mice and as a monotherapy, significantly inhibited the intraosseous growth of chemosensitive and chemoresistant PCa cells. These results indicate that BKM1972 is a promising small-molecule lead to treat PCa bone metastasis and overcome docetaxel resistance.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBone NeoplasmsBradykinin Receptor AntagonistsCell Line, TumorCell ProliferationDocetaxelHumansMaleMice, NudeMolecular Targeted TherapyOrganophosphonatesPhosphorylationProstatic NeoplasmsABCB1 protein, humanAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBIRC5 protein, humanBradykinin Receptor AntagonistsDocetaxelOrganophosphonatesSTAT3 protein, humanSTAT3 Transcription FactorSurvivinBone metastasisChemoresistancePreclinical modelProstate cancerSmall-molecule therapy

Identifiers

PMID30660650
PMCPMC6361683
OpenAlexW2910810461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.